Which has better earnings and valuation, MDCX or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A

Is MDCX or ALZN more profitable?

Alzamend Neuro's return on equity of -177.52% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Alzamend Neuro N/A -177.52% -140.41%

Do analysts prefer ALZN or NCEL?

Alzamend Neuro presently has a consensus price target of $28.00, indicating a potential upside of 2,422.52%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities analysts clearly believe Alzamend Neuro is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ALZN or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is ALZN or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% NLS Pharmaceutics N/A N/A N/A

Which has preferable valuation & earnings, ALZN or PASG?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is ALZN or PASG more profitable?

Passage Bio's return on equity of -150.88% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Passage Bio N/A -150.88% -59.78%

Do analysts recommend ZIVO or ALZN?

Alzamend Neuro has a consensus target price of $28.00, suggesting a potential upside of 2,422.52%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or ALZN more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Alzamend Neuro N/A -177.52% -140.41%

Is LEXX or ALZN more profitable?

Alzamend Neuro's return on equity of -177.52% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -206.02% -162.53% Alzamend Neuro N/A -177.52% -140.41%

Alzamend Neuro (ALZN) Competitors

$1.11 -0.03 (-2.63%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$1.12 +0.01 (+0.81%)

As of 06/5/2026 05:41 PM Eastern

Compare

ALZN vs. MDCX, NCEL, PASG, ZIVO, and LEXX

Should you buy Alzamend Neuro stock or one of its competitors? MarketBeat compares Alzamend Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alzamend Neuro include Medicus Pharma (MDCX), NLS Pharmaceutics (NCEL), Passage Bio (PASG), ZIVO Bioscience (ZIVO), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry.

How does Alzamend Neuro compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Alzamend Neuro's return on equity of -177.52% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Alzamend Neuro	N/A	-177.52%	-140.41%

Medicus Pharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

49.6% of Alzamend Neuro shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Medicus Pharma presently has a consensus price target of $9.00, indicating a potential upside of 2,471.43%. Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 2,422.52%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Medicus Pharma is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Medicus Pharma had 7 more articles in the media than Alzamend Neuro. MarketBeat recorded 7 mentions for Medicus Pharma and 0 mentions for Alzamend Neuro. Medicus Pharma's average media sentiment score of 0.51 beat Alzamend Neuro's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Medicus Pharma	Positive
Alzamend Neuro	Neutral

Summary

Medicus Pharma beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to NLS Pharmaceutics?

Alzamend Neuro (NASDAQ:ALZN) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

49.6% of Alzamend Neuro shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Alzamend Neuro presently has a consensus price target of $28.00, indicating a potential upside of 2,422.52%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities analysts clearly believe Alzamend Neuro is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
NLS Pharmaceutics	N/A	N/A	N/A

Alzamend Neuro has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

In the previous week, Alzamend Neuro's average media sentiment score of 0.00 equaled NLS Pharmaceutics'average media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
NLS Pharmaceutics	Neutral

Summary

Alzamend Neuro beats NLS Pharmaceutics on 5 of the 9 factors compared between the two stocks.

How does Alzamend Neuro compare to Passage Bio?

Alzamend Neuro (NASDAQ:ALZN) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Alzamend Neuro presently has a consensus price target of $28.00, indicating a potential upside of 2,422.52%. Passage Bio has a consensus price target of $13.25, indicating a potential upside of 135.77%. Given Alzamend Neuro's higher possible upside, equities analysts clearly believe Alzamend Neuro is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Passage Bio's return on equity of -150.88% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Passage Bio	N/A	-150.88%	-59.78%

Alzamend Neuro has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

In the previous week, Alzamend Neuro's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Passage Bio	Neutral

Summary

Passage Bio beats Alzamend Neuro on 8 of the 11 factors compared between the two stocks.

How does Alzamend Neuro compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ZIVO Bioscience's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Alzamend Neuro	N/A	-177.52%	-140.41%

Alzamend Neuro has a consensus target price of $28.00, suggesting a potential upside of 2,422.52%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ZIVO Bioscience had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Alzamend Neuro. ZIVO Bioscience's average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Alzamend Neuro	Neutral

ZIVO Bioscience has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Alzamend Neuro has lower revenue, but higher earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	798.97	-$7.78M	-$1.71	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Summary

Alzamend Neuro beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Lexaria Bioscience's average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
Alzamend Neuro	Neutral

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lexaria Bioscience has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Alzamend Neuro's return on equity of -177.52% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-206.02%	-162.53%
Alzamend Neuro	N/A	-177.52%	-140.41%

Alzamend Neuro has lower revenue, but higher earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	22.24	-$11.90M	-$0.47	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Lexaria Bioscience presently has a consensus target price of $1.50, suggesting a potential upside of 135.48%. Alzamend Neuro has a consensus target price of $28.00, suggesting a potential upside of 2,422.52%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alzamend Neuro beats Lexaria Bioscience on 6 of the 10 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.22M	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.56%
P/E Ratio	-0.51	18.69	24.03	23.62
Price / Sales	N/A	307.46	518.10	111.56
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	0.22	7.97	10.24	6.66
Net Income	-$4.51M	$23.89M	$3.57B	$337.55M
7 Day Performance	-6.72%	-6.96%	-1.28%	-2.52%
1 Month Performance	4.72%	-2.80%	1.38%	-0.03%
1 Year Performance	-69.34%	36.80%	23.93%	25.34%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	2.343 of 5 stars	$1.11 -2.6%	$28.00 +2,422.5%	-69.3%	$4.22M	N/A	N/A	4
MDCX Medicus Pharma	2.8133 of 5 stars	$0.29 -2.7%	$9.00 +2,982.2%	-87.3%	$17.00M	N/A	N/A	N/A	News Coverage Gap Down
NCEL NLS Pharmaceutics	1.1907 of 5 stars	$3.15 -0.3%	N/A	-87.3%	$16.89M	N/A	N/A	6	Gap Down
PASG Passage Bio	2.3225 of 5 stars	$5.55 +6.3%	$13.25 +138.7%	-33.5%	$16.76M	N/A	N/A	130
ZIVO ZIVO Bioscience	N/A	$4.00 -2.5%	N/A	-82.3%	$16.61M	$15.85K	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. MDCX, NCEL, PASG, ZIVO, and LEXX

How does Alzamend Neuro compare to Medicus Pharma?

Summary

How does Alzamend Neuro compare to NLS Pharmaceutics?

Summary

How does Alzamend Neuro compare to Passage Bio?

Summary

How does Alzamend Neuro compare to ZIVO Bioscience?

Summary

How does Alzamend Neuro compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. MDCX, NCEL, PASG, ZIVO, and LEXX

How does Alzamend Neuro compare to Medicus Pharma?

Which has better earnings and valuation, MDCX or ALZN?

Is MDCX or ALZN more profitable?

Which has more volatility & risk, MDCX or ALZN?

Do insiders and institutionals believe in MDCX or ALZN?

Do analysts prefer MDCX or ALZN?

Does the media refer more to MDCX or ALZN?

Summary

How does Alzamend Neuro compare to NLS Pharmaceutics?

Do institutionals and insiders believe in ALZN or NCEL?

Which has preferable valuation & earnings, ALZN or NCEL?

Do analysts prefer ALZN or NCEL?

Is ALZN or NCEL more profitable?

Which has more risk & volatility, ALZN or NCEL?

Does the media prefer ALZN or NCEL?

Summary

How does Alzamend Neuro compare to Passage Bio?

Do institutionals and insiders believe in ALZN or PASG?

Which has preferable valuation & earnings, ALZN or PASG?

Do analysts prefer ALZN or PASG?

Is ALZN or PASG more profitable?

Which has more risk & volatility, ALZN or PASG?

Does the media prefer ALZN or PASG?

Summary

How does Alzamend Neuro compare to ZIVO Bioscience?

Do institutionals & insiders hold more shares of ZIVO or ALZN?

Is ZIVO or ALZN more profitable?

Do analysts recommend ZIVO or ALZN?

Does the media favor ZIVO or ALZN?

Which has more risk & volatility, ZIVO or ALZN?

Which has higher valuation and earnings, ZIVO or ALZN?

Summary

How does Alzamend Neuro compare to Lexaria Bioscience?

Does the media refer more to LEXX or ALZN?

Do insiders and institutionals believe in LEXX or ALZN?

Which has more volatility & risk, LEXX or ALZN?

Is LEXX or ALZN more profitable?

Which has better valuation and earnings, LEXX or ALZN?

Do analysts rate LEXX or ALZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools